Chengda Pharmaceutical, following a self-inspection required by tax authorities, has paid back corporate income tax, property tax, value-added tax, surcharges, and late fees totaling 1.6377 million yuan. The payment has been completed and does not involve administrative penalties. The company stated that this back payment will be recorded in the current profit and loss for 2026, with the specific impact subject to the audited financial statements. Previously, Chengda Pharmaceutical had suffered losses for two consecutive years, with net losses of 28.1037 million yuan in 2024 and 11.9258 million yuan in 2025. In the first quarter of 2026, it achieved a net profit attributable to the parent company of 7.002 million yuan, a year-on-year increase of 600.15 percent.
ChengDa Pharmaceuticals Co. Ltd.Pays back taxes and late fees of 1.6377 million yuan, impacting 2026 net profit.